Jazz Pharmaceuticals To Present New Analysis Of Defibrotide Data In Patients With Hepatic Veno-Occlusive Disease At American Society of Hematology Annual Meeting /PRNewswire/ -- Jazz Pharmaceuticals plc announced today that researchers will present the results of a number needed to treat analysis from a historically controlled Phase 3 clinical trial evaluating the use of defibrotide for the treatment of severe hepatic veno-occlusive disease in patients undergoing hematopoietic stem-cell transplantation therapy. Researchers will also present updates from an international compassionate use program and an expanded access / treatment investigational new drug study in .
http://ift.tt/1wsZGML
http://ift.tt/1wsZGML
No comments:
Post a Comment